|
gptkbp:instanceOf
|
gptkb:drug
muscle relaxant
|
|
gptkbp:approvedBy
|
gptkb:Switzerland
|
|
gptkbp:ATCCode
|
M03BX01
|
|
gptkbp:bioavailability
|
70–80% (oral)
|
|
gptkbp:CASNumber
|
1134-47-0
|
|
gptkbp:chemicalClass
|
chlorophenyl derivatives
|
|
gptkbp:contraindication
|
hypersensitivity to baclofen
|
|
gptkbp:discoveredBy
|
gptkb:Ciba-Geigy
|
|
gptkbp:eliminationHalfLife
|
2–6 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:form
|
gptkb:tablet
oral suspension
solution for injection
|
|
gptkbp:hasMolecularFormula
|
C10H12ClNO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Baclofen
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:CNS_depressants
antihypertensives
|
|
gptkbp:introducedIn
|
1972
|
|
gptkbp:KEGGID
|
D00219
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GABA_B receptor agonist
|
|
gptkbp:MedlinePlusID
|
a682530
|
|
gptkbp:meltingPoint
|
206–208 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:overdoseSymptoms
|
coma
seizures
respiratory depression
|
|
gptkbp:pregnancyCategory
|
gptkb:B3
C
C (US)
|
|
gptkbp:proteinBinding
|
30%
|
|
gptkbp:PubChem_CID
|
2284
2198
DB00181
CHEMBL1387
|
|
gptkbp:riskOfWithdrawal
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
intrathecal
|
|
gptkbp:sideEffect
|
nausea
dizziness
fatigue
headache
drowsiness
weakness
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:synonym
|
gptkb:Lioresal
|
|
gptkbp:UNII
|
H789N3FKE8
|
|
gptkbp:usedFor
|
multiple sclerosis
spasticity
spinal cord injury
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:D00221
|
|
gptkbp:bfsLayer
|
7
|